Malignant lesions |
332/458 (72.5%) |
0.43–1.00 |
0.71 ± 0.12 |
Hepatocellular carcinoma |
254/347 (73.2%) |
0.43–1.00 |
0.72 ± 0.12 |
Liver metastasis |
30/51 (58.82%) |
0.52–1.00 |
0.70 ± 0.10 |
Intrahepatic cholangiocarcinoma |
35/44 (79.5%) |
0.51–1.00 |
0.68 ± 0.10 |
Mixed hepatocellular Cholangiocarcinoma |
3/5 (60%) |
0.68–0.82 |
0.73 ± 0.08 |
Sarcomatoid carcinoma |
3/4 (72.5%) |
0.69–0.72 |
0.71 ± 0.02 |
Epithelioid cell tumor |
3/3 (100%) |
0.45–0.59 |
0.51 ± 0.07 |
Benign lesions |
100/118 (84.7%) |
0.35 – 0.84 |
0.54 ± 0.10 |
Focal nodular hyperplasia |
48/52 (92.3%) |
0.40–0.69 |
0.54 ± 0.08 |
Angiomyolipoma |
15/16 (93.8%) |
0.35–0.72 |
0.51 ± 0.09 |
Hemangioma |
14/23 (60.9%) |
0.35–0.66 |
0.51 ± 0.09 |
Hepatocellular adenoma |
8/9 (88.9%) |
0.42–0.66 |
0.51 ± 0.08 |
Inflammatory pseudotumors |
4/5 (80%) |
0.58–0.84 |
0.68 ± 0.12 |